Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Odonate Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT04312282
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Annovera™ Drug-Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- TherapeuticsMD
- Target Recruit Count
- 67
- Registration Number
- NCT04290390
- Locations
- 🇨🇦
Syneos Health, Quebec City, Quebec, Canada
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04268394
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom
Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04266509
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 36
- Registration Number
- NCT04166669
- Locations
- 🇳🇱
PRA-EDS, Groningen, Netherlands
🇳🇱PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, Netherlands
Efficacy and Safety of Intravenous Treatment of Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Yuria-Pharm
- Target Recruit Count
- 166
- Registration Number
- NCT04150367
- Locations
- 🇺🇦
Regional Antituberculosis Dispensary, Kherson, Ukraine
🇺🇦Regional Clinical Antituberculosis Dispensary, Sumy, Ukraine
🇺🇦Regional phthisiopulmonary center, Ivano-Frankivs'k, Ukraine
A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 80
- Registration Number
- NCT04142762
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Beta Pharma, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04135833
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04121078
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04118842
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.